Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost adults who use Wegovy for weight management need to stay on it long-term to maintain the results. The weight loss the medicine produces depends on the drug being active in your system; when treatment stops, appetite typically returns to its previous level and weight tends to come back, often within months. That is not a character flaw — it reflects the biology of how GLP-1 medicines work. Wegovy (semaglutide) is licensed in the UK as an ongoing treatment, not a short course, and the clinical guidance from NICE for NHS use specifies a maximum of two years, a restriction that applies specifically to the NHS pathway, not to private prescribing, where duration is decided between you and your prescriber based on how you are responding.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The honest answer is that for most people, yes, Wegovy is closer to a chronic condition medicine than a short treatment you finish. The STEP 1 trial published in the New England Journal of Medicine showed roughly 15% average body-weight reduction over 68 weeks on 2.4 mg semaglutide. A withdrawal study that followed STEP 1 participants found that a year after stopping treatment, most of the weight had returned. That pattern is consistent enough that UK clinical guidance treats Wegovy as a long-term intervention.
This is where many people feel a flicker of frustration, a reasonable reaction when the implication is open-ended treatment. But the framing matters: obesity is a chronic, relapsing condition shaped by hormones and genetics, not a temporary problem to be fixed and filed away. Semaglutide addresses part of the underlying biology. Remove it, and the biology reasserts itself.
That said, individual responses vary. Some patients lose substantial weight, make lasting changes to eating habits and activity, and feel confident discussing a planned stop with their prescriber. Others choose to continue indefinitely because the health benefits, including improvements to blood pressure, blood sugar and sleep apnoea, remain clinically meaningful. If you are weighing up how long you may have to take Wegovy, the answer depends on your personal health picture and is best worked through with your prescriber rather than a forum. The conversation about how long you personally need to stay on Wegovy belongs with your prescriber, not a forum.
NICE's appraisal of semaglutide for weight management (TA875) recommends its use for a maximum of two years within a specialist weight management service on the NHS. That limit was set partly on the basis of cost-effectiveness modelling over a defined treatment period and the evidence available at the time of appraisal, and it applies to the NHS commissioning framework, not to the medicine's actual product licence.
The UK product licence for Wegovy does not impose a two-year cut-off. In a private setting like ours, your prescriber makes the duration decision on clinical grounds: how much weight you have lost, whether weight-related conditions have improved, how well you are tolerating the medicine, and whether the benefits continue to outweigh the risks. There is no automatic stop point.
One threshold does apply across both settings: if you have not lost at least 5% of your body weight after six months at the highest tolerated maintenance dose, clinical guidance recommends reviewing whether continuing makes sense. That review is a clinical conversation, not a blunt rule, it exists to avoid long-term treatment that is not working for you. You can read more about how long Wegovy typically takes to produce visible results if you are earlier in treatment.
Weight regain after stopping is well-documented. In practice, appetite increases relatively quickly once semaglutide clears the system, and food intake rises to match. The rate of regain varies between individuals, but the withdrawal data suggest most regain begins within weeks and becomes substantial within six to twelve months. This is not a sign that treatment failed, it is the expected pharmacology of stopping a medicine that was actively suppressing appetite.
People who have used the treatment period to build sustainable habits around eating and activity tend to regain less. That is not guaranteed, but it is a consistent enough pattern that our prescribers discuss it as part of ongoing care. The early months of treatment are often when habits shift most noticeably, which is why wraparound dietary support matters throughout.
If you are thinking about stopping, do so with your prescriber's input rather than abruptly. There is no clinical danger in stopping semaglutide, but planning the transition (including monitoring and support) makes a meaningful difference to what comes next. You can also explore what other weight management options might be appropriate alongside or after Wegovy. Curious about the cost of private Wegovy treatment and what is included? Our treatment page has current pricing in full.
Yes, restarting is medically possible and is not unusual. If weight has returned and the original reasons for treatment still apply, a prescriber may recommend restarting from a lower dose to allow your system to readjust, the titration schedule exists partly to reduce nausea, and reintroducing at a high dose after a break tends to increase side effects. Whether you restart depends on the same clinical factors as starting: BMI, comorbidities, what else you have tried, and what your health goals are.
At nume, every repeat order (including a restart after a break) is reviewed by one of our GPhC-registered prescribers before anything is dispensed. That clinical re-review is not a formality; it is the point at which current weight, any changes to health history and ongoing suitability are all assessed. A prescriber who knows your case is the right person to advise on timing and dose. If you have questions about your current treatment or want to discuss your options, our team is reachable through our contact page seven days a week.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.